Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06410924
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-05-08
Brief Title:
A Study to Evaluate DD01 in OverweightObese Subjects With MASLDMASH
Sponsor:
Neuraly Inc
Organization:
Neuraly Inc
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Placebo-Controlled Parallel Group Study to Evaluate the Efficacy Safety and Tolerability of Treatment With DD01 for 48 Weeks in OverweightObese Subjects With MASLDMASH
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweightobese patients with metabolic dysfunction-associated steatotic liver disease MASLDmetabolic dysfunction-associated steatohepatitis MASH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None